Eadie, L N
Hughes, T P
White, D L
Article History
First Online: 2 December 2016
Competing interests
: TPH and DLW receive honoraria and research funds from Novartis Pharmaceuticals, and are members of Advisory Boards for Novartis. TPH is a chair of the CML/MPN disease group for the Australasian Leukaemia and Lymphoma Group (ALLG). Neither Novartis nor ALLG had roles in the design of the study, collection and analysis of the data or the decision to publish. LNE declares no conflict of interest.